Paola Corti

Paola Corti

Auto-generated profile, based on publicly available information

Paola Corti

Pediatric Hematology‐Oncology Department University of Milano‐Bicocca, MBBM Foundation, San Gerardo Hospital Monza Italy

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2017 in Blood Cells, Molecules, and Diseases
Verified
Journal Article
Closed access
AMAngela Mercuri
Angela Mercuri
PFPiero Farruggia
Piero Farruggia
FTFabio Timeus
Fabio Timeus
LLLaura Lombardi
Laura Lombardi
DODaniela Onofrillo
Daniela Onofrillo
Simone CesaroSimone Cesaro
Simone Cesaro


6 September 2023 in British Journal of Haematology
Verified
Journal Article
Open access
VMV. Munaretto
V. Munaretto
PCP. Corti
P. Corti
EBE. Bertoni
E. Bertoni
STS. I. Tripodi
S. I. Tripodi
MGM. E. Guerzoni
M. E. Guerzoni
RCRaffaella Colombatti
Raffaella Colombatti
Summary: Acute chest syndrome (ACS) is a frequent cause of hospitalization in sickle cell disease (SCD). Despite advances in acute care, many settings still lack knowledge about ACS best practices. After the AIEOP Guidelines were published in 2012, suggesting standardized management in Italy, a retrospective study was performed to assess the diagnostic and therapeutic pathways of ACS in children. From 2013 to 2018, 208 ACS episodes were presented by 122/583 kids in 11 centres. 73 were male, mean age 10.9 years, 85% African, 92% HbSS or Sβ°. In our hub‐and‐spoke system, a good adherence to Guidelines was documented, but discrepancies between reference centres and general hospitals were noted. Improvement is needed for timely transfer to reference centres, use of incentive spirometry, oxygen therapy and pain management.

27 September 2022 in Children
Verified
Journal Article
Open access
PDF file
MGMARIA ELENA GUERZONI
MARIA ELENA GUERZONI
SMStefano Marchesi
Stefano Marchesi
GPgiovanni palazzi
giovanni palazzi
MLMariachiara Lodi
Mariachiara Lodi
MPMargherita Pinelli
Margherita Pinelli
Lorenzo IughettiLorenzo Iughetti
Lorenzo Iughetti
Background: Environmental factors seem to influence clinical manifestations of sickle cell disease (SCD), but few studies have shown consistent findings. We conducted a retrospective multicentric observational study to investigate the influence of environmental parameters on hospitalization for vaso-occlusive crises (VOC) or acute chest syndrome (ACS) in children with SCD. Methods: Hospital admissions were correlated with daily meteorological and air-quality data obtained from Environmental Regional Agencies in the period 2011–2015. The effect of different parameters was assessed on the day preceding the crisis up to ten days before. Statistical analysis was performed using a quasi-likelihood Poisson regression in a generalized linear model. Results: The risk of hospitalization was increased for low maximum temperature, low minimum relative humidity, and low atmospheric pressure and weakly for mean wind speed. The diurnal temperature range and temperature difference between two consecutive days were determined to be important causes of hospitalization. For air quality parameters, we found a correlation only for high levels of ozone and for low values at the tail corresponding to the lowest concentration of this pollutant. Conclusions: Temperature, atmospheric pressure, humidity and ozone levels influence acute complications of SCD. Patients’ education and the knowledge of the modes of actions of these factors could reduce hospitalizations.


21 November 2023 in British Journal of Haematology
Verified
Journal Article
Open access
PCPaola Corti
Paola Corti
GFGiulia Maria Ferrari
Giulia Maria Ferrari
MFMartha Caterina Faraguna
Martha Caterina Faraguna
GCGiulia Capitoli
Giulia Capitoli
FLFilomena Longo
Filomena Longo
APAlberto Piperno
Alberto Piperno
Summary: Haemochromatosis (HC) encompasses a range of genetic disorders. HFE‐HC is by far the most common in adults, while non‐HFE types are rare due to mutations of HJV, HAMP, TFR2 and gain‐of‐function mutations of SLC40A1. HC is often unknown to paediatricians as it is usually asymptomatic in childhood. We report clinical and biochemical data from 24 paediatric cases of HC (10 cases of HFE‐, 5 TFR2‐, 9 HJV‐HC), with a median follow‐up of 9.6 years. Unlike in the adult population, non‐HFE‐HC constitutes 58% (14/24) of the population in our series. Transferrin saturation was significantly higher in TFR2‐ and HJV‐HC compared to HFE‐HC, and serum ferritin and LIC were higher in HJV‐HC compared to TFR2‐ and HFE‐HC. Most HFE‐HC subjects had relatively low ferritin and LIC at the time of diagnosis, so therapy could be postponed for most of them after the age of 18. Our results confirm that HJV‐HC is a severe form already in childhood, emphasizing the importance of early diagnosis and treatment to avoid the development of organ damage and reduce morbidity and mortality. Although phlebotomies were tolerated by most patients, oral iron chelators could be a valid option in early‐onset HC.